Mubarak Al-Kabeer Hospital, Jabriya, Kuwait.
Al Jahra Hospital, Al Jahra, Kuwait.
Rheumatol Int. 2019 Sep;39(9):1483-1497. doi: 10.1007/s00296-019-04372-y. Epub 2019 Jul 15.
The Kuwait Association of Rheumatology (KAR) aimed to develop a set of recommendations for the treatment of patients with rheumatoid arthritis (RA), tailored to the unique patient population and healthcare system of Kuwait. Each recommendation was developed based on expert opinion and evaluation of clinical practice guidelines from other international and national rheumatology societies. Online surveys were conducted to collate feedback on each KAR member's level of agreement (LoA) with definitions of disease-/treatment-related terms used and the draft recommendations. Definitions/recommendations achieving a pre-defined cut-off value of ≥ 70% agreement were accepted for inclusion. Remaining statements were discussed and revised at a face-to-face meeting, with further modifications until consensus was reached. A final online survey was used to collect feedback on each KAR member's LoA with the final set of recommendation statements on a scale of 0 (complete disagreement) to 10 (complete agreement). Group consensus was achieved on 66 recommendation statements, including 3 overarching principles addressing the pharmacological treatment and management of RA. Recommendations focused on treatment of early RA, established RA, patients with high-risk comorbidities, women during pregnancy and breastfeeding, and screening and treatment of opportunistic infections. The KAR 2018 Treatment Recommendations for RA reported here are based on a synthesis of other national/international guidelines, supporting literature, and expert consensus considering the Kuwaiti healthcare system and RA patient population. These recommendations aim to inform the clinical decisions of rheumatologists treating patients in Kuwait, and to promote best practices, enhance alignment and improve the treatment experience for patients.
科威特风湿病学会 (KAR) 旨在制定一套针对类风湿关节炎 (RA) 患者的治疗建议,这些建议根据专家意见和对来自其他国际和国家风湿病学会的临床实践指南的评估,针对科威特独特的患者群体和医疗保健系统进行定制。
在线调查被用来收集每位 KAR 成员对用于疾病/治疗相关术语的定义以及草案建议的认同程度的反馈。达到预先定义的 ≥70% 认同度的定义/建议被接受纳入。其余的陈述在面对面会议上进行了讨论和修订,并进行了进一步的修改,直到达成共识。最后,使用在线调查收集每位 KAR 成员对最终建议陈述的认同程度的反馈,从 0(完全不同意)到 10(完全同意)进行评分。
在 66 项建议陈述上达成了共识,其中包括 3 项针对 RA 药物治疗和管理的总体原则。建议侧重于早期 RA、确诊 RA、有高风险合并症的患者、妊娠和哺乳期妇女以及机会性感染的筛查和治疗。
这里报告的 2018 年 KAR RA 治疗建议是基于对其他国家/国际指南、支持文献以及考虑到科威特医疗保健系统和 RA 患者群体的专家共识的综合。这些建议旨在为在科威特治疗患者的风湿病学家提供临床决策信息,并促进最佳实践、加强一致性和改善患者的治疗体验。